Antiretroviral therapy at conception in pregnant women with HIV in Italy: Wide range of variability and frequent exposure to contraindicated drugs

Marco Floridia, Enrica Tamburrini, Marina Ravizza, Gianfranco Anzidei, Cecilia Tibaldi, Anna Bucceri, Anna Maccabruni, Giovanni Guaraldi, Alessandra Meloni, Maria Fernanda Ravagni Probizer, Brunella Guerra, Pasquale Martinelli

Research output: Contribution to journalArticlepeer-review

Abstract

Methods: Data from a large national surveillance study was used to describe antiretroviral regimens in pregnant women with HIV, with particular reference to the presence at conception of antiretroviral treatments contraindicated in pregnancy. Therapeutic changes during pregnancy were also analysed. Results: Among 334 women on antiretroviral treatment at conception, less than half (42.4%) reported current pregnancy as planned. A large number of different regimens (80) was observed. All the regimens included at least one nucleoside or nucleotide reverse transcriptase inhibitor. Non-nucleoside reverse transcriptase inhibitors and protease inhibitors were present in similar proportions (39.2% and 40.7%, respectively). The most commonly used drugs were lamivudine (83.2% of regimens), zidovudine (50.0%). stavudine (d4T; 38.0%), nevirapine (25.7%), didanosine (ddl; 17.7%) and nelfinavir (17.7%). Treament with efavirenz (13.5% of regimens) and ddl+d4T (9.6%) was markedly frequent. Use of efavirenz at conception was associated with a subsequent treatment change during pregnancy (odds ratio [OR]: 13.2.; 95% confidence interval [CI]: 3.2-53.8, P

Original languageEnglish
Pages (from-to)941-946
Number of pages6
JournalAntiviral Therapy
Volume11
Issue number7
Publication statusPublished - 2006

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Antiretroviral therapy at conception in pregnant women with HIV in Italy: Wide range of variability and frequent exposure to contraindicated drugs'. Together they form a unique fingerprint.

Cite this